Back to User profile » Dr Jason Bacharach
Papers published by Dr Jason Bacharach:
Efficacy and Safety of Preservative-Free Bimatoprost 0.01% Gel in Patients with Open-Angle Glaucoma and Ocular Hypertension: Results from Two Phase III Randomized Trials
Bacharach J, Miller-Ellis E, Harasymowycz P, Peace JH, Nissle S, Day DG, Stalmans I
Clinical Ophthalmology 2026, 20:571715
Published Date: 12 April 2026
Expert Opinion to Optimize Clinical Outcomes of Bimatoprost Intracameral Implant Treatment
Bovee C, Bacharach J, Singh IP, Swaminathan SS, Bovelle R, Lai H, Rivas M, Vera V
Clinical Ophthalmology 2025, 19:4027-4042
Published Date: 31 October 2025
The Effect of Eyedrop Size on Pupillary Dilation Using the Nanodropper Bottle Adapter
Chow A, Choi J, Bacharach J
Clinical Ophthalmology 2025, 19:1217-1221
Published Date: 6 April 2025
Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study
Bacharach J, Sadri E, Sawhney G, Kopczynski C, Merchea MM
Clinical Ophthalmology 2025, 19:175-186
Published Date: 21 January 2025
Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial [Corrigendum]
Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C
Clinical Ophthalmology 2023, 17:2763-2764
Published Date: 19 September 2023
Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial
Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C
Clinical Ophthalmology 2023, 17:2575-2588
Published Date: 1 September 2023
Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
Schechter BA, Urbieta M, Bacharach J, Toyos M, Smyth-Medina R, Mitchell B, Luchs JI
Clinical Ophthalmology 2022, 16:4145-4151
Published Date: 13 December 2022
First Real-World, Multicenter, Post-Marketing, Retrospective Study of Dexamethasone Intraocular Suspension for Inflammation After Cataract Surgery
Bacharach J, McCabe C, Jackson M, Rao S, Singh IP, Heersink S, Radcliffe N, Weinstock R, Paggiarino D, Patel K
Clinical Ophthalmology 2022, 16:1783-1794
Published Date: 3 June 2022
Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
Wirta DL, Korenfeld MS, Foster S, Smyth-Medina R, Bacharach J, Kannarr SR, Jaros MJ, Slonim CB
Clinical Ophthalmology 2021, 15:4035-4048
Published Date: 8 October 2021
Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results
Bacharach J, Wirta DL, Smyth-Medina R, Korenfeld MS, Kannarr SR, Foster S, Jaros MJ, Slonim CB
Clinical Ophthalmology 2021, 15:2743-2751
Published Date: 25 June 2021
Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
Shen Lee B, Kabat AG, Bacharach J, Karpecki P, Luchs J
Clinical Ophthalmology 2020, 14:119-126
Published Date: 14 January 2020